Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs eBay Inc (EBAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs eBay Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.25 (market cap $29.60B), while eBay Inc trades at $102.87 (market cap $47.17B). The key difference: eBay Inc is the larger of the two by market cap, and eBay Inc pays a 1.17% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EBAY | |
|---|---|---|
Market Cap | $29.60B | $47.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $118.96 |
52-Week Low | $205.48 | $79.41 |
Enterprise Value | $27.56B | $51.00B |
Volume | — | 5,186,418 |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
EBAY stock trades at $102.62, down 4.73% on news that GameStop may abandon its $56 billion takeover bid in favor of a partnership. The stock exhibits a bearish technical signal with key support at $104, while fundamentals show strong profitability with an 18.57% net income margin and consistent earnings beats in recent quarters. Revenue growth is projected to reach $12.0 billion in 2026, though cash flow turned negative in 2025.
The outlook is mixed: analyst consensus targets $119.31 with 46% buy ratings, but near-term sentiment is pressured by takeover uncertainty. Risks include competitive threats in e-commerce and reliance on focus categories. Upside hinges on execution of live shopping initiatives and potential partnership benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →
